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(TD50 = 30); insulins (TD50 = 45); antidepressants (TD50 = 67);
bisphosphonates (TD50 = 82); cardiovascular agents (TD50 = 85);
statins (TD50 = 90); oral antidiabetic agents (TD50 = 90); and
glaucoma medications (TD50 = 120). Rates of medication dis-
continuation among patients who had ﬁlled a prescription
for an in-class medication in the prior 180 days were: inhaled
steroids (TD50 = 60); insulins (TD50 = 130); glaucoma medica-
tions (TD50 = 180); antidepressants (TD50 = 187); cardiovascular
agents (TD50 = 240); oral antidiabetic agents (TD50 = 270);
bisphosphonates (TD50 = 272); and statins (TD50 = 308).
CONCLUSIONS: Patients new to therapy faced a far higher
likelihood of medication discontinuation compared to those with
prior in-class medication experience among all the medication
classes studied. Providers and health care systems may want to
re-engineer care to provide more frequent follow-up and educa-
tion to this commonly treated, high-risk group.
PRS20
SYSTEMATIC REVIEW OF FIXED-DOSE COMBINATIONS
AND UNIT-OF-USE PACKAGING IN PATIENTS WITH
HYPERTENSION, DYSLIPIDEMIA,AIDS,ASTHMA AND
DIABETESTYPE 2
Paladio N,Almazan C, Moharra M
Catalan Agency for Health Technology Assessment and Research,
Barcelona, Spain
OBJECTIVES: Poor compliance is the primary reason for sub-
optimal clinical beneﬁt, especially in patients with chronic dis-
eases. Fixed-dose combinations (FDC) and unit-of-use packaging
(UUP) are strategies designed to simplify medication regimen and
potentially improve compliance. The aim of our study is to
systematically analyze the effect of FDC and UUP on compliance
and effectiveness in patients with hypertension (HTA), dyslipi-
demia, AIDS, asthma and diabetes type 2 (DMII). METHODS:
Systematic review (SR) of studies that compare medications com-
bined in a single pill or within a UUP with the same free-drug
combinations in HTA, AIDS, asthma and DMII. Bibliographic
databases were searched from inception to February 2008 with
no date limits. Two reviewers scrutinized retrieved references and
full publications sought of potentially relevant studies were iden-
tiﬁed on the basis of title and/or abstract. Additional relevant
studies were identiﬁed from manual searches. Only studies pub-
lished in English or Spanish were included. Quality of studies was
assessed using speciﬁc instruments according to their design.
RESULTS: A total of 11 original studies (HTA 5; DMII 3; AIDS
2; dyslipidemia 1), 1 SR and 1 metaanalysis of varying quality
were included in the SR. Most originals were retrospective
(72%), based on medical claims (72%) and used medication
possession ratio (RPM) as a proxy of compliance (54%). Some
studies also included self-reported compliance (27%) and mea-
sures of persistence (18%). Only 3 studies reported comparative
effectiveness. Follow-up periods ranged from 16 weeks to 1 year.
Overall, results show a tendency for better compliance and less
missed doses in the FDC and UPP groups compared to free-drug
combination groups. Limited data support noninferiority of FDC
and UUP in terms of effectiveness. CONCLUSIONS: FDC and
UUP seem to improve compliance with no major effects on
effectiveness in patients with chronic diseases. However, evidence
is weak and large randomized controlled trials should be carried
out.
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OBJECTIVES: Health-related quality of life data are frequently
collected in clinical trials from different countries and combined
in analyses. This analysis compared AQLQ data across 16 coun-
tries (17 languages) to evaluate suitability to combine data in
subsequent analyses. METHODS: AQLQ data from the Gaining
Optimal Asthma controL (GOAL) study was used for the analy-
ses. Of 3416 patients treated, 1973 had an overall AQLQ score
at baseline, 1850 at week 12 and 1832 at both. The original
language (North American English) was considered the reference
language (RL). Values within 0.5 of the RL were considered
comparable given that 0.5 is considered a clinically meaningful
difference. RESULTS: Number of patients completing each
AQLQ language varied from 27 (Canadian French) to 256 (Man-
darin Chinese). Mean age ranged from 31.7 years (Spain) to 52.9
years (Norway) and percent of males ranged from 30.3% (Brazil)
to 74.4% (Norway). Mean overall AQLQ score [s.d.] at baseline
in the RL was 4.59 [0.94]. Of the 16 languages all but three,
Chile (3.58 [1.05]), Denmark (5.10 [0.82]) and Spain (5.19
[0.93]), reported mean baseline AQLQ overall scores within 0.5
of the RL. Similar ﬁndings were reported for AQLQ domain
scores, with few countries reporting baseline values outside 0.5
of the RL. Mean change from baseline in the overall AQLQ score
in the RL was 0.89 [1.06], with all translations reporting values
within 0.5 of the RL indicating similar results in all languages.
For the AQLQ domains, only the emotional function domain of
the Norwegian, Canadian French and French for France trans-
lations were outside 0.5 of the RL. CONCLUSIONS: The con-
sistency of baseline and change from baseline scores comparing
16 translations with the original language version supports the
validity of translations used in this study and the combining of
data across countries for analyses.
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OBJECTIVES: Health-related quality of life data are frequently
collected in clinical studies from a number of countries and
combined for analysis. This study compared AQLQ data across
16 countries (17 languages) to investigate if the measurement
properties of the AQLQ are sufﬁciently consistent to support
combining data in multinational trials. METHODS: The AQLQ
data from the Gaining Optimal Asthma controL (GOAL) study
was used for the analyses. Of 3416 patients treated, 1973 had
an overall AQLQ score at baseline, 1850 at week 12 and 1832
at both. The original language (North American English) was
considered the reference language (RL). Internal consistency,
construct validity and responsiveness were evaluated for each
translation. RESULTS: Number of patients completing each
AQLQ language varied from 27 (Canadian French) to 256 (Man-
darin Chinese) with 81 patients completing the RL. Mean age
ranged from 31.7 years (Spain) to 52.9 years (Norway) and
percent of males ranged from 30.3% (Brazil) to 74.4%
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